Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.67 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 5/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12100341 | 0.82 | KDM4E (0.60) | KDM4EALOX15HSD17B10MAPTMAPK1 | |
| SCHEMBL5090417 | 0.80 | KMT2A (0.56) | KDM4EALOX15HSD17B10MAPTMAPK1 | |
| SCHEMBL8915404 | 0.78 | ALDH1A1 (0.49) | KDM4EALOX15HSD17B10MAPTMAPK1 | |
| SCHEMBL22904177 | 0.75 | MAPT (0.64) | KDM4EALOX15HSD17B10MAPTMAPK1 | |
| SCHEMBL13664157 | 0.74 | GAA (0.58) | KDM4EALOX15HSD17B10MAPTMAPK1 | |
| SCHEMBL13664209 | 0.73 | MAPT (0.58) | KDM4EMAPTKMT2AALDH1A1HPGD | |
| SCHEMBL13664169 | 0.72 | ALDH1A1 (0.46) | KDM4EALOX15HSD17B10MAPTMAPK1 | |
| SCHEMBL18988298 | 0.72 | ADORA1 (0.48) | KDM4EALOX15HSD17B10MAPTMAPK1 | |
| SCHEMBL13664164 | 0.72 | MAPK14 (0.49) | KDM4EALOX15HSD17B10MAPTMAPK1 | |
| SCHEMBL13664172 | 0.71 | MAPT (0.64) | KDM4EHSD17B10MAPTALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090253673-A1 | Substituted Pyrazoles as Ghrelin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2009-10-08 | — | — | US | disclosed |
| US-20090253673-A1 | Substituted Pyrazoles as Ghrelin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253673-A1 | Substituted Pyrazoles as Ghrelin Receptor Antagonists | GIPR, GPR119, GLP1R | KDM4E 3380/4885ALOX15 3066/4885HSD17B10 1099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.